Saatja: <
[email protected]>
Saadetud: 27.11.2020 19:28
Koopia: <
[email protected]>
Teema: C.L.53.2020 (Covax Facility)
Dear Member States of the World Health Organization,Please find attached,
in the six official languages, C.L.53.2020 regarding the product
liability and product labelling issues that will impact access to COVID-
19 vaccines distributed through the COVAX Facility.Should you have
questions regarding C.L.53.2020 please send an email to .Best
regards,Department of Governing BodiesWorld Health Organization
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.53.2020
Product liability and product labelling issues that will impact access to
COVID-19 vaccines distributed through the COVAX Facility
The Director-General of the World Health Organization (WHO) presents his compliments
to WHO Member States and has the honour to refer to the COVAX Facility, the Global Vaccine
Facility of the Access to COVID-19 Tools (ACT) Accelerator, that WHO is co-leading with
Gavi, the Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI).
One of the overarching objectives of the COVAX Facility is to facilitate the equitable
access to COVID-19 vaccines distributed under COVAX. Given the unprecedented nature and
scale of the COVID-19 pandemic, as well as the speed at which COVID-19 vaccines are being
developed and are expected to be deployed on a global basis, the Director-General would like to
bring Member States’ attention to two important issues that will impact countries’ access to such
vaccines. These issues are: (i) adequately addressing product liability risks associated with
COVID-19 vaccines distributed under COVAX; and (ii) exercising necessary product labelling
exemptions, as labelling compliant with national requirements may not be available from the
outset of deployment.
The Director-General is inviting Member States to ensure that the following actions in the
areas of product liability risks and product labelling are promptly taken to avoid any limits or
delays in accessing COVID-19 vaccines distributed under COVAX.
Addressing product liability risks (including through implementing legislation, if needed)
The COVAX Facility is working to find a practical solution to the issue of liability in
respect of COVID-19 vaccines distributed under COVAX, as manufacturers have expressed
reluctance to deliver COVID-19 vaccines to countries participating in COVAX unless product
liability risks are adequately addressed. The solution aims to be equitable to all stakeholders and
mitigate anticipated financial risks to the Advance Market Commitment (AMC)-eligible
economies, as much as reasonably possible. The three main pillars of the solution are: (i) a
requirement that all countries participating in COVAX enter into indemnification agreements
with vaccine manufacturers; and, for AMC-eligible economies only; (ii) the issuance of
indemnity backstopping guarantees by a third party; and (iii) the establishment of a
compensation mechanism to compensate individuals suffering serious adverse events associated
with COVID-19 vaccines distributed under COVAX. Information on the proposed liability
solution can be found at: https://www.gavi.org/sites/default/files/covid/covax/BRIEFING-
NOTE-Indemnification-and-Compensation-COVAX-AMC-Countries.pdf.
Page 2
C.L.53.2020
The Director-General hereby invites Member States to take urgent actions to:
1. Determine whether implementing legislation needs to be enacted within their country
to enable governments to indemnify manufacturers and other relevant stakeholders and/or
to enable persons within their country to accept payments under the proposed COVAX
compensation mechanism in full and final settlement of any claims.
2. If any such legislation is needed based on the above, draft and enact all necessary
implementing legislation as soon as possible before the supply of COVID-19 vaccines
under COVAX commences.
COVAX is seeking to obtain dedicated advisory support to assist AMC-eligible
economies, should they so desire, in respect of the actions above.
Product labelling
COVID-19 vaccines are being manufactured ahead of the decisions on countries in which
they may ultimately be deployed. This advanced manufacturing is necessary to ensure the rapid
deployment of the vaccines once regulatory approval and policy decisions have been made to
deploy the vaccines. There is, however, no universal agreement for the format and content of
vaccine vial and packaging labels. Multiple, country-specific national requirements are not
compatible with timely access to these potentially lifesaving vaccines. WHO has developed
models for vials and secondary packaging to unify the labelling requirements for vaccines that
will be supplied through the COVAX Facility. The model labels, relevant for vaccines supplied
through UN procurement agencies, are available at: https://www.who.int/teams/regulation-
prequalification/eul/covid-19/covid-19-model-packaging.
Similarly WHO has developed working positions to leverage the use of 2D bar code
technology on secondary packaging in the context of traceability systems, and the use of QR
code technologies on primary and/or secondary packaging for supplemental electronic access to
label and leaflet information (considered optional, and not in lieu of related statutory
requirements). The working positions can be accessed at:
https://www.who.int/publications/m/item/bar-codes-qr-codes-and-vaccine-vial-monitors-in-the-
context-of-covid-19-vaccines.
Member States are invited to take the following urgent actions:
1. Determine under what provisions the national medicines regulatory authority can
issue an exemption for certain labelling requirements for COVID-19 vaccines distributed
under COVAX.
Page 3
C.L.53.2020
2. Ensure that the national medicines regulatory authority can:
(i) authorize COVID-19 vaccines distributed by the COVAX Facility that are
labelled in compliance with the WHO models;
(ii) authorize the translated label information in local languages (i.e. other than the
six UN official languages) for printing and distribution.
The Director-General of the World Health Organization takes the opportunity to renew to
Member States the assurance of his highest consideration.
GENEVA, 27 November 2020